Evaluation of Apligraf® persistence and basement membrane restoration in donor site wounds: A pilot study

Wound Repair and Regeneration

Volumn 14, Issue 4, 2006, Pages 427-433

  Hu, Shasa ^a   Kirsner, Robert S ^a,b   Falanga, Vincent ^c,d   Phillips, Tania ^d   Eaglstein, William H ^a,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e IVAX Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYTOKINE; DNA; HLA ANTIGEN CLASS 2; POLYURETHAN; APLIGRAF;

ADULT; AGED; ARTICLE; ARTIFICIAL SKIN; BASEMENT MEMBRANE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC FOOT; DONOR SITE; EPITHELIUM; FEMALE; FIBROBLAST; HLA TYPING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LEG ULCER; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAFETY; SKIN; TISSUE ENGINEERING; WOUND; WOUND CLOSURE; WOUND HEALING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMIS; INJURY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PENETRATING TRAUMA; PHYSIOLOGY; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSPLANTATION;

ADULT; BASEMENT MEMBRANE; COLLAGEN; DERMIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SKIN; SKIN, ARTIFICIAL; TISSUE AND ORGAN HARVESTING; WOUND HEALING; WOUNDS, PENETRATING;

EID: 33747619395     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2006.00148.x     Document Type: Article

References (33)

1. Brem H, Balledux J, Sukkarieh T, Carson P, Falanga V. Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. Dermatol Surg 2001; 27: 915-9.
2. Brem H, Balledux J, Bloom T, Kerstein MD, Hollier L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 2000; 135: 627-34.
3. Allie DE, Hebert CJ, Lirtzman MD, Wyatt CH, Keller VA, Souther SM, Allie AA, Mitran EV, Walker CM. Novel treatment strategy for leg and sternal wound complications after coronary artery bypass graft surgery: bioengineered Apligraf. Ann Thorac Surg 2004; 78: 673-8; discussion 678.
4. Muhart M, McFalls S, Kirsner RS, Elgart GW, Kerdel F, Sabolinski ML, Hardin-Young J, Eaglstein WH. Behavior of tissue-engineered skin: a comparison of a living skin equivalent, autograft, and occlusive dressing in human donor sites. Arch Dermatol 1999; 135: 913-8.
5. Waymack P, Duff RG, Sabolinski M. The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. The Apligraf burn study group. Burns 2000; 26: 609-19.
6. Trent JT, Kirsner RS. Epidermolysis bullosa: identification and treatment. Adv Skin Wound Care 2003; 16: 284-90.
7. Fivenson DP, Scherschun L, Choucair M, Kukuruga D, Young J, Shwayder T. Graftskin therapy in epidermolysis bullosa. J Am Acad Dermatol 2003; 48: 886-92.
8. Phillips TJ, Manzoor J, Rojas A, Isaacs C, Carson P, Sabolinski M, Young J, Falanga V. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol 2002; 138: 1079-81.
9. Kirsner RS, Falanga V. Techniques of split-thickness skin grafting for lower extremity ulcerations. J Dermatol Surg Oncol 1993; 19: 779-83.
10. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993; 41: 119-34.
11. Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F, Altman M, Jensen J, Sabolinski M, Hardin-Young J. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human skin equivalent investigators group. Arch Dermatol 1998; 134: 293-300.
12. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24: 290-5.
13. Falabella AF, Valencia IC, Eaglstein WH, Schachner LA. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol 2000; 136: 1225-30.
14. Gordon S, Bui A. Human skin equivalent in the treatment of chronic leg ulcers in sickle cell disease patients. J Am Pediatr Med Assoc 2003; 93: 240-1.
15. de Imus G, Golomb C, Wilkel C, Tsoukas M, Nowak M, Falanga V. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol 2001; 44: 61-6.
16. Martin LK, Kirsner RS. Ulcers caused by bullous morphea treated with tissue-engineered skin. Int J Dermatol 2003; 42: 402-4.
17. Horn WA. Graftskin heals an ulcer on an amputation stump. Dermatol Surg 2000; 26: 946-8.
18. Sabolinski ML, Alvarez O, Auletta M, Mulder G, Parenteau NL. Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers. Biomaterials 1996; 17: 311-20.
19. Theobald VA, Lauer JD, Kaplan FA, Baker KB, Rosenberg M. "Neutral allografts" - lack of allogeneic stimulation by cultured human cells expressing MHC class I and class II antigens. Transplantation 1993; 55: 128-33.
20. Briscoe DM, Dharnidharka VR, Isaacs C, Downing G, Prosky S, Shaw P, Parenteau NL, Hardin-Young J. The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection. Transplantation 1999; 67: 1590-9.
21. Eaglstein WH, Iriondo M, Laszlo K. A composite skin substitute (graftskin) for surgical wounds. A clinical experience. Dermatol Surg 1995; 21: 839-43.
22. Eaglstein WH, Alvarez OM, Auletta M, Leffel D, Rogers GS, Zitelli JA, Norris JE, Thomas I, Irondo M, Fewkes J, Hardin-Young J, Duff RG, Sabolinski ML. Acute excisional wounds treated with a tissue-engineered skin (Apligraf). Dermatol Surg 1999; 25: 195-201.
23. Griffiths M, Ojeh N, Livingstone R, Price R, Navsaria H. Survival of Apligraf in acute human wounds. Tissue Eng 2004; 10: 1180-95.
24. Tyring SK, Chopra V, Johnson L, Fine JD. Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa. Arch Dermatol 1989; 125: 797-800.
25. Brain A, Purkis P, Coates P, Hackett M, Navsaria H, Leigh I. Survival of cultured allogeneic keratinocytes transplanted to deep dermal bed assessed with probe specific for Y chromosome. BMJ 1989; 298: 917-9.
26. Badiavas EV, Paquette D, Carson P, Falanga V. Human chronic wounds treated with bioengineered skin: histologic evidence of host-graft interactions. J Am Acad Dermatol 2002; 46: 524-30.
27. Phillips TJ, Kehinde O, Green H, Gilchrest BA. Treatment of skin ulcers with cultured epidermal allografts. J Am Acad Dermatol 1989; 21: 191-9.
28. Teepe RG, Koebrugge EJ, Ponec M, Vermeer BJ. Fresh versus cryopreserved cultured allografts for the treatment of chronic skin ulcers. Br J Dermatol 1990; 122: 81-9.
29. Kirsner RS, Falanga V, Eaglstein WH. The biology of skin grafts. Skin grafts as pharmacologic agents. Arch Dermatol 1993; 129: 481-3.
30. Osborne CS, Schmid P. Epidermal-dermal interactions regulate gelatinase activity in Apligraf, a tissue-engineered human skin equivalent. Br J Dermatol 2002; 146: 26-31.
31. Falanga V, Isaacs C, Paquette D, Downing G, Kouttab N, Butmarc J, Badiavas E, Hardin-Young J. Wounding of bioengineered skin: cellular and molecular aspects after injury. J Invest Dermatol 2002; 119: 653-60.
32. Vaalamo M, Leivo T, Saarialho-Kere U. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing. Hum Pathol 1999; 30: 795-802.
33. Herrick SE, Ireland GW, Simon D, McCollum CN, Ferguson MW. Venous ulcer fibroblasts compared with normal fibroblasts show differences in collagen but not fibronectin production under both normal and hypoxic conditions. J Invest Dermatol 1996; 106: 187-93.